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Background: To investigate the relationship between health-related quality of life (HRQOL) and survival in Chinese
patients with chronic liver disease (CLD).
Methods: HRQOL was measured with the Chinese version of Short Form 36 (SF-36). SF-36 scores, demographic and
clinical data were collected at baseline and after 18 months follow-up. Kaplan-Meier and Cox Proportional Hazard
Regression survival analyses were used for interpretation of data. Surviving patients were censored in the analyses.
Results: A total of 415 Chinese patients with CLD and 86 healthy controls were enrolled. During the follow-up
period 50 patients died. SF-36 scores in healthy controls and surviving patients were higher compared with those
in deceased patients. Scores of physical component summary (PCS) in healthy controls, surviving and deceased
patients were 54.1 ± 5.2, 48.9 ± 7.7 and 33.5 ± 8.2 respectively (p < 0.001). Scores of mental component summary
(MCS) in healthy controls, surviving and deceased patients were 56.6 ± 8.2, 53.0 ± 5.6 and 37.1 ± 12.1 (p < 0.001)
respectively. Survival was significantly associated with PCS and MCS scores, and the presence of ascites.
Conclusions: HRQOL was associated with survival in patients with CLD. PCS and MCS scores were predictors of survival.
Keywords: Health-related quality of life, Chronic liver disease, SF-36, SurvivalIntroduction
Chronic liver disease (CLD) is known to cause significant
morbidity and mortality, typically due to a number of
complications that include ascites, hepatic encephalop-
athy, variceal hemorrhage and hepatorenal syndrome
[1,2]. CLD negatively impacts health-related quality of life
(HRQL) [3-6] with patients suffering from fatigue, loss of
self-esteem, an inability to function at work, anxiety, de-
pression and other emotional problems that profoundly de-
crease their quality of life and well-being [7-13]. Although
recent research shows that HRQOL scores are independent
prognostic factors for overall survival in patients with
unresectable hepatocellular carcinoma (HCC) and can
predict survival in liver transplant candidates [14-17],
the relationship between HRQOL and survival in pa-
tients with CLD remains unclear. Therefore, the aim of
this study was to examine whether scores from the Short
Form 36 (SF-36) health survey are able to predict survival
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Ethics
The study received ethics approval from the Ethics Board
of Beijing Chao-Yang Hospital, Capital Medical University
and all participants gave written informed consent.Patient selection
Between September 2009 and September 2011, eligible
patients with CLD, aged 18 to 80 years from the Digestive
Department of Beijing Chao-Yang Hospital, Capital Medical
University were approached to participate in the study.
Patients with other chronic active medical diseases
(such as congestive heart failure, chronic obstructive pul-
monary disease), psychiatric conditions, malignancy, liver
transplantation and those unable to communicate or who
declined to participate were excluded. Patients with hepa-
titis B virus (HBV) infection and chronic hepatitis C virus
(HCV) infection or who received interferon therapy in the
previous 3 months were also excluded. The healthy con-
trols consisted of individuals without chronic disease, aged
18 to 80 years, male or female and who regularly under-
took health screening in our hospital’s health examination. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of unpredictable events, social and environmental factors.
Each patient had an established diagnosis confirmed by a
Hepatologist. The diagnosis of chronic HBV infection was
based on the presence of hepatitis B surface antigen for
more than six months, elevated serum alanine aminotrans-
ferase levels, with or without HBV DNA as detected by the
hybridization method [18]. The diagnosis of chronic HCV
infection was based on a positive hepatitis C antibody
(ELISA II analysis), elevated serum alanine aminotransfer-
ase levels, with or without HCV RNA as detected by poly-
merase chain reaction [19]. The diagnosis of primary biliary
cirrhosis was based on a positive antimitochondrial anti-
body and elevated liver enzymes with or without liver bi-
opsy [20]. Alcohol was deemed the etiology of chronic liver
disease if daily alcohol consumption was greater than 40 g
for at least 10 years with elevated γ-glutamyl transferase
and exclusion of other liver diseases [21]. The diagnosis of
autoimmune hepatitis was based on simplified diagnostic
criterion [22]. The diagnosis of liver cirrhosis was based on
clinical, biochemical, serologic, ultrasonographic and radio-
graphic parameters.
Data collection
On admission, patients gave written informed consent and
completed the self-administered HRQOL questionnaire.
The Medical Outcomes Study of Short Form36 (SF-36 v2Table 1 Demographic data of different groups
Items Healthy control
n = 86 n %
Age (mean ± SE, yr) 53.1 ± 13.1
Male/Female (n) 51/35 59/41
Paired/Single (n) 84/2 98/2
Educational level (n)
Primary school 10 11
Middle school 54 63
College or University 18 21
College above 4 5










AIH Autoimmune Hepatitis, ALD Alcoholic Liver Disease, CHB Chronic Hepatitis B, CHChinese version) is a widely used and validated generic
HRQOL questionnaire. Extensive demographic and clinical
data were collected on admission and marital status was
dichotomized into single and paired; single was extended to
include unmarried persons, divorced or deceased couples.
Laboratory data included alanine and aspartate amino-
transferases, alkaline phosphatase, γ-glutamyl transferase,
total bilirubin, serum albumin, serum creatine, prothrom-
bin time, serum potassium and sodium, hemoglobin, white
blood cell and platelet counts (DADE Dimension Rx1
full-automatic biochemical analyzer).
HRQOL survey
The SF-36 v2 Chinese Version (from Quality Metric
Incorporated) consists of 36 items divided into eight
domains that are aggregated into two summary scores,
a mental component summary (MCS) and a physical
component summary (PCS). These domains range from
reflecting predominantly physical wellbeing, that include
physical function (PF), the ability to perform expected
physical roles (RP), the degree of bodily pain (BP) and
overall sense of general health (GH) to those reflecting
predominantly social and emotional well-being that in-
clude overall sense of vitality (VT), ability to function
in social roles (SF), ability to perform expected emo-
tional and social roles (RE) and overall sense of mental
health (MH) [23-25].Chronic liver disease Independent sample
t test or Chi-squaren = 415 n %
54.2 ± 13.4 P = 0.441
243/172 58/42 P = 0.898






Cirrhosis n % Cirrhosis n % –
16 4 18 5 –
62 15 54 13 –
54 13 64 15
28 7 36 9 –
34 8 35 8 –
– 14 3 –
– 158 38 –
– 196 47 –
– 84 20 –
C Chronic Hepatitis C, PBC primary biliary cirrhosis.
Table 2 HRQOL and clinical data of different groups (mean ± SE)
Items Healthy control Chronic liver disease ANOVA
Surviving patients Deceased patients
n = 86 n = 365 n = 50
Physical function 93.2 ± 6.4 86.6 ± 15.4 70.1 ± 29.9 P < 0.001
Physical roles 88.8 ± 15.6 80.5 ± 19.3 63.0 ± 32.6 P < 0.001
Bodily pain 85.1 ± 15.1 87.3 ± 14.2 72.9 ± 26.2 P < 0.001
General health 75.3 ± 18.1 56.3 ± 21.3 44.9 ± 28.7 P < 0.001
Vitality 83.5 ± 12.0 76.1 ± 10.7 42.7 ± 21.9 P < 0.001
Social roles 94.1 ± 10.6 81.0 ± 20.0 39.5 ± 21.0 P < 0.001
Emotional roles 92.9 ± 10.7 89.6 ± 13.4 54.4 ± 26.3 P < 0.001
Mental health 87.9 ± 25.0 79.3 ± 11.0 52.2 ± 23.4 P < 0.001
PCS 54.1 ± 5.2 48.9 ± 7.7 33.5 ± 8.2 P < 0.001
MCS 56.6 ± 8.2 53.0 ± 5.6 37.1 ± 12.1 P < 0.001
Laboratory data
Albumin (g/L) 37.0 ± 2.7 35.3 ± 7.4 24.5 ± 4.8 P < 0.001
ALT (U/L) 23.0 ± 10.4 56.3 ± 62.8 37.8 ± 31.7 P = 0.001
AST (U/L) 23.4 ± 12.7 63.3 ± 69.5 82.7 ± 69.4 P < 0.001
GGT (U/L) 51.8 ± 58.0 102.8 ± 146.3 123.9 ± 216.9 P = 0.088
ALP (U/L) 105.6 ± 72.0 126.8 ± 94.9 140.7 ± 128.0 P = 0.267
TBIL (umol/L) 9.4 ± 3.9 26.8 ± 35.7 81.4 ± 77.1 P < 0.001
BUN (umol/L) 5.0 ± 0.9 5.4 ± 2.8 9.9 ± 7.4 P < 0.001
Cr (umol/L) 68.8 ± 14.7 77.2 ± 26.0 109.1 ± 65.5 P < 0.001
Prothrombin time (s) 10.5 ± 0.5 13.3 ± 2.8 18.3 ± 5.7 P < 0.001
WBC (109/L) 6.0 ± 1.4 4.7 ± 2.0 5.6 ± 4.7 P < 0.001
Hemoglobin (g/L) 136.0 ± 19.8 118.7 ± 25.4 90.6 ± 20.7 P < 0.001
Platelet (109/L) 210.4 ± 35.0 131.1 ± 75.3 77.3 ± 44.5 P < 0.001
K (mmol/L) 4.0 ± 0.3 4.0 ± 0.4 3.8 ± 0.7 P = 0.041
Na (mmol/L) 140.2 ± 3.5 140.8 ± 7.9 135.7 ± 6.9 P < 0.001
PCS physical component summary, MCS mental component summary, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase,
GGT γ-glutamyl transferase, TBIL total bilirubin, Cr serum creatine, BUN blood urea nitrogen, K serum potassium, Na serum sodium, WBC white blood cell.
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We followed all participants longitudinally and terminated
the follow-up at the time of the patient’s death or March
1st, 2013, whichever occurred first.
Comparison groups
After the follow-up period, patients were divided into
survival and deceased groups.
Statistical methods
Categorical data were described as the number and con-
tinuous data as mean ± SE. Data were analyzed using
independent sampled t test, one-way analysis of variance
(ANOVA) or Chi-square test. Univariate Cox Proportional
Hazard Regression analysis was conducted for PCS, MCS,
demographic and clinical variables. Variables with a p
value <0.1 in univariate Cox Proportional Hazard Regression
analysis were entered into multivariate Cox ProportionalHazard Regression analysis. Survival curves were estimated
with the Kaplan-Meier method across the quartiles of PCS
and MCS scores. A p value <0.05 was considered as statisti-
cally significant. All data were analyzed with SAS 9.1.
Results
Demographic and clinical data of respondents
A total of 415 Chinese patients with CLD and 86 healthy
controls were enrolled and 18 months of follow-up was
completed. A total of 50 patients died and two patients
were treated with liver transplantation, one in our hos-
pital and one in a different hospital. Both patients died
within one month and were therefore excluded from the
analysis. The duration of follow-up for surviving and
deceased patients was 30.7 ± 10.0 months and 12.1 ±
5.8 months respectively. A further 22 patients were lost
to follow up and were also excluded from the analysis.
There were no significant difference between the groups
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or educational level (Table 1).
Quality of life and clinical data of respondents
All scores for SF-36 were significantly lower in deceased
patients compared with surviving patients with CLD and
healthy controls (Table 2). Laboratory results from
deceased patients showed significantly lower levels of
albumin, hemoglobin, platelet count, serum potassium
and serum sodium and significantly higher levels of
total bilirubin, prothrombin time, blood urea nitrogen
and serum creatinine.
Cox proportional hazard regression
All variables related to survival with a p value of <0.1 in the
univariate analyses were subjected to multivariate analyses.Table 3 Results of Cox regression analyses
Variables Univariate
HR (95% CI) P
Physical function 0.971 (0.961–0.981) P
Physical roles 0.973 (0.963–0.983) P
Bodily pain 0.964 (0.952–0.977) P
General health 0.979 (0.967–0.991) P
Vitality 0.911 (0.898–0.925) P
Social roles 0.934 (0.921–0.947) P
Emotional roles 0.935 (0.924–0.945) P
Mental health 0.925 (0.913–0.937) P
PCS 0.852 (0.826–0.880) P
MCS 0.856 (0.834–0.878) P
Age 1.059 (1.034–1.084) P
Etiology 1.118 (0.967–1.294) P
MELD 1.121 (1.074–1.170) P
Ascites 89.883 (12.40–651.0) P
ALT 0.992 (0.983–1.000) P
AST 1.003 (1.000–1.006) P
PT 1.197 (1.152–1.243) P
TBIL 1.011 (1.008–1.014) P
WBC 1.132 (1.045–1.227) P
HGB 0.964 (0.954–0.974) P
PLT 0.985 (0.979–0.992) P
Albumin 0.803 (0.766–0.843) P
Cr 1.012 (1.008–1.015) P
BUN 1.132 (1.096–1.169) P
K 0.451 (0.243–0.837) P
Na 0.979 (0.968–0.990) P
PCS physical component summary, MCS mental component summary, MELD model
aminotransferase, PT Prothrombin Time, TBIL total bilirubin, Cr serum creatine, BUN
cell. Etiology includes autoimmune Hepatitis, alcoholic Liver Disease, chronic Hepat
score of multivariate is 369.08 and P <0.001.PCS scores, MCS scores and the presence of ascites were
significantly associated with survival (Table 3). For a one
point increase of PCS, the risk of death was reduced by
0.099. For a point increase of MCS, the risk of death re-
duced by 0.124. The presence of ascites increased the risk
of death by 7.432. Model Fit Statistics (AIC) for multivariate
was 369.08 (p < 0.001).
Kaplan-Meier analysis
Survival was significantly different across the quartiles of
PCS scores, MCS scores and with the presence of ascites
(Figures 1, 2, 3 and 4). Three points of quartile for PCS
were 43.5, 50.6, 55.2, and for MCS were 48.9, 53.5, 57.4.
Three points of quartile for PCS with the presence of
ascites were 33.0, 40.8, 45.8, and for that of MCS were
43.3, 51.2, 55.8.Multivariate









<0.001 0.901 (0.867–0.935) P <0.001




<0.001 8.432(1.117–63.63) P = 0.038
= 0.056 – –











for end stage liver disease, ALT alanine aminotransferase, AST aspartate
blood urea nitrogen, K serum potassium, Na serum sodium, WBC white blood
itis B, chronic Hepatitis C, and primary biliary cirrhosis. Model Fit Statistics (AIC)
Figure 1 Kaplan-Meier analysis showing association between PCS scores and survival, log-rank P < 0.001.
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The results from this study show that deceased patients
with CLD had a poor baseline quality of life and a poor
clinical state compared with patients who survived. Base-
line HRQOL scores were also much worse compared with
healthy controls. Recent studies have shown that patients
with CLD have substantially reduced HRQOL scores,
however, the scores do not differ markedly according
to the etiology of the disease. Increasing disease severity isFigure 2 Kaplan-Meier analysis showing association between MCS scoalso associated with a poor HRQOL, particularly for the
physical component [3-5,10-13]. With progression of liver
dysfunction, patients with CLD suffer from fatigue, loss of
self-esteem, an inability to function at work, anxiety, de-
pression and other emotional problems that profoundly
decrease their quality of life and well-being [23,26]. Fur-
thermore, patients with CLD suffer from complications
that reduce their HRQOL, especially for the physical do-
main area and are less able to maintain daily work and liferes and survival, log-rank p < 0.001.
Figure 3 Kaplan-Meier analysis showing association between PCS scores plus present ascites and survival, log-rank p < 0.001.
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CLD had impaired HRQOL and increasing severity of
CLD was associated with a decreasing HRQOL score [31].
Old age, female gender, advanced stage of CLD, presence
of ascites, hyperbilirubinemia and a prolonged prothrom-
bin time were important factors in reducing HRQOL.
In this study, patients with higher PCS and MCS scores
had a markedly increased survival rate. In a recent report,
PCS but not MCS scores from the SF-36 predicted survival
[16]. Another report showed that disease-specific HRQOL
components, rather than PCS and MCS can be used to
identify patients with advanced liver disease who are at high
risk of short-term death [17]. There are several possible rea-
sons for this discrepancy. Firstly, the intervention of liver
transplantation can markedly improve HRQOL, especiallyFigure 4 Kaplan-Meier analysis showing association between MCS scothe physical domains, however, in our study, patients only
received medical treatment where liver transplantation
would have been appropriate, but is limited by funding
issues (15 cases per annum receive liver transplantation in
our hospital). With progression of liver dysfunction, pa-
tients with cirrhosis suffer from fatigue, loss of self-esteem,
inability to function at work, anxiety, depression and other
emotional problems that profoundly decrease their quality
of life and well-being [23,26]. Our previous study showed
reduced MCS scores with increasing severity of CLD
[31]. Secondly, most patients in our study were relatively
stable with a lower mean score of MELD (mean = 7.7) and
only 12% died during the follow-up period of 18 months.
Therefore, both PCS and MCS were significantly associated
with survival.res plus present ascites and survival, log-rank p < 0.001.
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associated with reduced survival, a finding not documented
in previous studies even though ascites is the most
common complication of advanced CLD. The presence of
ascites is regarded as a serious manifestation of advanced
CLD and reflects the onset of liver decompensation with an
increased mortality (15% in the first year and 44% in the
5 years after diagnosis). Ascites usually becomes refractory
to diuretic control with progression of CLD, where survival
rates approach 50% at one year [32].
HRQOL measures, such as the SF-36, a generic ques-
tionnaire, is used to measure HRQOL in the general
population and in patients with chronic diseases includ-
ing CLD. Many research centers have used HRQOL to
compare CLD patients with healthy controls and have
generally reported impairment of HRQOL. Additionally,
measurement of HRQOL can facilitate integration of
biomedical and psychosocial models of health. This in-
tegrated approach in the study of patients with CLD will
capture the impact of these diseases on patient’s health and
well-being [23-30]. Several recent studies have established
that better HRQOL is an independent predictor of survival
in many chronic diseases such as end-stage renal disease,
congestive heart failure, type 2 diabetes and various cancers
[33-36]. Further studies also suggest that HRQOL could
be used to predict survival of patients with advanced
CLD [14,16,17]. Therefore, measurement of HRQOL might
compliment objective measures of disease severity to not
only accurately and comprehensively assess health status,
but also to better stratify risk in patients with CLD.
Our study has a number of limitations. All subjects were
recruited from one hospital in one city. Our hospital is
a public general affiliated hospital of Capital Medical
University and three levels of first-class or China’s most
senior hospital in Beijing. Our department has 42 beds
including an endoscopy suite. We serve over 150,000
outpatients per year, over 1,800 in-patients per year
and over 20000 endoscopies per year that might intro-
duce selection bias. Our sample consisted mostly of
patients with health insurance who have better access
to healthcare. Therefore, our patient sample excludes
patients without health insurance with limited access
to care. Our study included patients with CLD with
different etiologies and severity. We are addressing these
issues in ongoing studies by assessing a larger group of
patients in multiple centers.Summary
HRQOL was associated with survival in patients with
CLD. PCS and MCS scores were predictors of survival.Competing interests
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